Cerca Articoli

Trovati 15 risultati per "Regulation" (Pagina 2 di 2) 213.13ms • aggiornato
Chemicals: New European Commission determined to make REACH a success

Chemicals: New European Commission determined to make REACH a success

Vice President Tajani and Commissioner Poto?nik have swiftly followed up on their undertaking given during their Hearings in the European Parliament by together visiting the European Chemicals Agency, ECHA, in Helsinki on 25 March. They are taking action to make progress towards the registration of chemicals and the management of substances of very high concern. Of particular importance is the smooth implementation of the registration of high-volume chemicals by the REACH deadline of 30 November 2010 by implementing solutions to practical problems to support industrys work, in particular SMEs. Both Commissioners also announced their common approach on the identification and management of substances of very high concern. They also welcomed progress on the translation of the guidelines for the implementation of REACH. Both commissioners underlined their commitment to the success of REACH, the European Chemicals Regulation.

Redazione Health 29 Mar 2010
300.0K 0
Broadband : Commission consults on regulatory strategy to promote very high speed Internet

Broadband : Commission consults on regulatory strategy to promote very high speed Internet

T he European Commission has launched a public consultation on its revised proposals for the regulation of Next Generation Access (NGA) broadband networks, in the form of a draft Commission Recommendation. A previous public consultation held during the last quarter of 2008 confirmed general support for the objective of the Commission to achieve a common regulatory framework for NGA in order to foster timely investment in very high speed networks while ensuring that the competitive structure of the market is maintained. In the light of comments from stakeholders, the revised draft Recommendation includes mechanisms to allocate the investment risk between investors and operators seeking access to NGA networks. The draft Recommendation forms part of the European Broadband Strategy that the March European Council invited the Commission to develop by the end of 2009. The public consultation will be open until 24 July 2009. The Commission plans to adopt the Recommendation, taking account of comments received, before the end of 2009.

Redazione Internet 23 Jun 2009
177.9K 0
Keratinocyte Growth Factor Receptor Restores 5-Fluorouracil and Tamoxifen Efficacy on Resp

Keratinocyte Growth Factor Receptor Restores 5-Fluorouracil and Tamoxifen Efficacy on Resp

Silencing of Keratinocyte Growth Factor Receptor Restores 5-Fluorouracil and Tamoxifen Efficacy on Responsive Cancer Cells.Sabrina Rotolo 1, Simona Ceccarelli 1, Ferdinando Romano 1, Luigi Frati 1,2, Cinzia Marchese 1, Antonio Angeloni 1* 1 Dipartimento di Medicina Sperimentale, Universita` Sapienza di Roma, Roma, Italy, 2 Istituto Neurologico Mediterraneo ‘‘Neuromed, Pozzilli, ItalyAbstract : BackgroundKeratinocyte growth factor receptor (KGFR) is a splice variant of the FGFR2 gene expressed in epithelial cells. Activation of KGFR is a key factor in the regulation of physiological processes in epithelial cells such as proliferation, differentiation and wound healing. Alterations of KGFR signaling have been linked to the pathogenesis of different epithelial tumors. It has been also hypothesized that its specific ligand, KGF, might contribute to the development of resistance to 5-fluorouracil (5-FU) in epithelial cancers and tamoxifen in estrogen-positive breast cancers.Abstract : Methodology/Principal FindingsSmall interfering RNA was transfected into a human keratinocyte cell line (HaCaT), a breast cancer derived cell line (MCF-7) and a keratinocyte primary culture (KCs) to induce selective downregulation of KGFR expression. A strong and highly specific reduction of KGFR expression was observed at both RNA (reduction = 75.7%, P = 0.009) and protein level. KGFR silenced cells showed a reduced responsiveness to KGF treatment as assessed by measuring proliferation rate (14.2% versus 39.0% of the control cells, P

Redazione Health 03 Jul 2008
180.0K 0
Precedente Pagina 2 di 2